IDM Junovan Has August User Fee Date For Osteosarcoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Treatment has orphan drug status, but was not granted a priority review by FDA.
You may also be interested in...
IDM Foresees Junovan Approval In 2007 Following Pre-NDA Meeting
Firm preps response to FDA info request, gears for 2006 filing of bone cancer therapy.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
CEO Clozel discusses the firm’s renin inhibitor program in the face of Novartis’ Tekturna, alliances with Merck and Roche and its business strategy going forward.
Actelion CEO Jean-Paul Clozel: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Exec discusses the firm’s pulmonary arterial hypertension drug Tracleer and other endothelin receptor antagonists in Actelion’s pipeline.